Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP (APPRAISE ATP)
Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP (APPRAISE ATP)
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.
Inclusion Criteria:
Subject with a Boston Scientific transvenous ICD (de novo implant or upgrade from pacemaker to ICD) implanted because of one of the following:
Subject is age 21 or above, or is considered of legal age per given geography
Subject is willing and capable of providing informed consent
Subject is willing and capable of complying with follow-up visits as defined by this protocol
Exclusion Criteria:
Salisbury, Maryland 21804, United States
Kalamazoo, Michigan 49048, United States
Philadelphia, Pennsylvania 19104, United States
Kitakyushu-Shi, Fukuoka 802-8555, Japan
Sagamihara-shi, Kanagawa 252-0375, Japan
Nagaoka-shi, Niigata 940-8621, Japan
Hidaka-shi, Saitama 350-1298, Japan